Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 11

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer

Authors Szucs TD, Szillat KP, Blozik E

Received 17 October 2017

Accepted for publication 24 January 2018

Published 23 April 2018 Volume 2018:11 Pages 67—69

DOI https://doi.org/10.2147/PGPM.S154368

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth


Thomas D Szucs,1 Kevin P Szillat,2 Eva Blozik3

1University of Basel, Institute of Pharmaceutical Medicine (ECPM), Basel, Switzerland; 2Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zürich, Switzerland; 3Department of Health Sciences, Helsana Group, Zürich, Switzerland


Abstract: Single-nucleotide polymorphisms (SNPs) can severely impact individual drug response and health outcomes in cancer patients. Genetic tests to screen for marker SNPs are available to adjust the drug dose of oncologicals to the patient’s needs. However, it is unclear whether the positive effects outbalance the increased costs or even lead to an overall cost reduction. This very pragmatic analysis used three frequently used oncologicals for the treatment of breast cancer to evaluate whether preemptive pharmacogenetic testing may have a cost-reducing impact on health care spending in the Swiss health care system. Our results indicate that oncopharmacogenetics might help to reduce health care costs (ie, by avoiding adverse drug effects) and to increase efficiency of drugs in oncologic patients.

Keywords: pharmacogenetics, oncology, budget impact model, Switzerland, health insurance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]